Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 clinical trial of MZE782 in chronic kidney disease

Next Previous
Trial Profile

A Phase 2 clinical trial of MZE782 in chronic kidney disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MZE 782 (Primary)
  • Indications Renal failure
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 27 Oct 2025 New trial record
  • 06 Oct 2025 According to a Maze Therapeutics media release, initial topline data from the trial in expected in 2026.
  • 11 Sep 2025 According to Maze Therapeutics media release, has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $150.0 million. Maze intends to use these proceeds together with its existing cash, cash equivalents and short-term investments, to initiate Phase 2 clinical trials of MZE782 in both phenylketonuria and chronic kidney disease, along with other research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top